文献速递肿瘤 PET/CT神经核医学核素与放射性配体治疗

[68Ga]Ga-SSO120 PET/CT 在小细胞肺癌和大细胞神经内分泌肺癌中的恶性肿瘤检出率

Malignancy Detection Rates of [68Ga]Ga-SSO120 PET/CT in Patients with Small Cell Lung Cancer and Large Cell Neuroendocrine Lung Cancer.
PubMed 文献 · J Nucl Med · 2026-04-01

这项前瞻性 2 期横断面影像试验对 19 例小细胞肺癌(SCLC)和大细胞神经内分泌肺癌(LCNEC)患者进行了 21 次 [68Ga]Ga-SSO120 PET/CT,评估恶性肿瘤检出率。结果显示 18 例患者(95%)可检出病灶,肺、区域淋巴结和胸外灵敏度分别为 82%、83% 和 93%,但 PET 检出的病灶数显著少于 CT(P=0.037),同时 PET 在 5 例患者中额外发现 10 处转移。

要点

  • [68Ga]Ga-SSO120 PET/CT 在 95% 的 SCLC/LCNEC 患者中可检出病灶。
  • PET 检出病灶数显著少于 CT(P=0.037),尤其小肺病灶、区域淋巴结和肝病灶。
  • PET 在 5 例患者中额外识别 10 处转移(骨 7、小脑 1、皮下 2)。

核心结论

  • [68Ga]Ga-SSO120 PET/CT 可在化疗期间及化疗后成功显示 SCLC 和 LCNEC 病灶。
  • 支持开展以 [177Lu]Lu-SSO110 为配对治疗药物的治疗学研究。

研究设计与样本

  • 前瞻性、2 期、横断面影像试验,共对 19 例患者进行 21 次 [68Ga]Ga-SSO120 PET/CT。
  • 19 例患者中 16 例为 SCLC、2 例为 LCNEC、1 例为 SCLC/LCNEC 混合型。
  • 11 例在姑息化疗期间扫描,8 例在监测期扫描。

主要发现

  • 18 例患者(95%)可检出 [68Ga]Ga-SSO120 阳性病灶。
  • 肺、区域淋巴结和胸外区域的灵敏度分别为 82%、83% 和 93%。
  • [68Ga]Ga-SSO120 PET 检出病灶数显著少于 CT(P=0.037),尤其在小肺病灶、区域淋巴结和肝病灶方面。
  • PET 在 5 例患者中额外识别 10 处转移:骨 7 处、小脑 1 处、皮下 2 处。
  • 恶性病灶 SUVmax 中位数为 7.4(范围 4.6-26.4),与诊断后时间、末次化疗后时间、治疗周期数或当前进展无显著关联。

临床怎么用

  • 在 SCLC 和 LCNEC 患者中,[68Ga]Ga-SSO120 PET/CT 可辅助检出病灶,但病灶检出数少于 CT。
  • PET 可额外发现骨、小脑和皮下等转移灶,提示其在分期或监测中的补充价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The primary aim of this study was to investigate the malignancy detection rate of [68Ga]Ga-SSO120 ([68Ga]Ga-satoreotide trizoxetan) PET/CT in patients with small cell lung cancer (SCLC) and large cell neuroendocrine lung cancer (LCNEC). Secondary aims included investigations of lesion-based detection rates and quantification. Methods: In this prospective, phase 2, cross-sectional imaging trial, 21 [68Ga]Ga-SSO120 PET/CTs were performed for 19 patients. Overall detection rates, lesion-based detection rates, and number of identified lesions were compared between [68Ga]Ga-SSO120 PET and CT. The [68Ga]Ga-SSO120 SUVmax, SUVpeak, SUVmean, and tumor-to-liver ratios in malignant lesions and selected normal tissue were quantified. Results: Nineteen patients (16 with SCLC, 2 with LCNEC, and 1 with combined SCLC/LCNEC) were scanned during palliation chemotherapy (n = 11) or surveillance (n = 8). [68Ga]Ga-SSO120-detectable lesions were identified in 18 patients (95%). Sensitivity in the lungs, regional lymph nodes, and extrathoracic regions was 82%, 83%, and 93%, respectively. [68Ga]Ga-SSO120 PET detected significantly fewer lesions than did CT (P = 0.037), particularly small lung lesions, regional lymph nodes, and liver lesions. In contrast, [68Ga]Ga-SSO120 PET identified 10 additional metastases in 5 patients (bone, 7; cerebellum, 1; subcutaneous, 2). SUVmax (median, 7.4; range, 4.6-26.4) was not significantly associated with time since diagnosis, time since last chemotherapy, number of treatment cycles, or current progression. Conclusion: [68Ga]Ga-SSO120 PET/CT successfully visualized SCLC and LCNEC lesions during and after chemotherapy. Therapeutic studies with [177Lu]Lu-SSO110 ([177Lu]Lu-satoreotide tetraxetan), the theranostic companion of [68Ga]Ga-SSO120, PET are warranted.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Christensen TN, Langer SW, Dejanovic D, et al. Malignancy Detection Rates of [68Ga]Ga-SSO120 PET/CT in Patients with Small Cell Lung Cancer and Large Cell Neuroendocrine Lung Cancer. J Nucl Med. 2026. PMID: 41506802. doi:10.2967/jnumed.125.270233

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。